Lung cancer

McGonigle, Niall

doi:10.1016/j.mpsur.2020.03.008

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poor prognosis and increased mortality among lung cancer patients are often associated with advanced age and stage at diagnosis, identified in half of all patients [5,6]. The elderly are more likely to be diagnosed with lung cancer and to experience comorbidity (coexistence of an additional chronic disease) or multimorbidity (coexistence of more than two chronic diseases) with a primary condition [7,8].…”

Section: Introductionmentioning

confidence: 99%

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study

et al. 2021

View full text Add to dashboard Cite

Aim Chronic diseases often occur simultaneously and tend to be associated with adverse health outcomes, but limited research has been undertaken to understand their role in lung cancer mortality. Therefore, this study aims to describe the prevalence and patterns of having one (comorbidity) or ≥ 2 chronic diseases (multimorbidity) among lung cancer patients in Spain, and to examine the association between comorbidity or multimorbidity and short-term mortality risk at six months after cancer diagnosis. Methods In this population-based cohort study, data were drawn from two Spanish population-based cancer registries, Girona and Granada, and electronic health records. We identified 1259 adult lung cancer patients, diagnosed from 1st January 2011 to 31st December 2012. We identified the most common patterns of individual comorbidities and their pairwise correlations. We used a flexible parametric modelling approach to assess the overall short-term mortality risk 6 months after cancer diagnosis by levels of comorbidity after adjusting for age, sex, smoking status, province of residence, surgery, cancer stage, histology, and body mass index. Results We found high prevalence of comorbidity in lung cancer patients, especially among the elderly, men, those diagnosed with advanced-stage tumours, smokers, and obese patients. The most frequent comorbidities were chronic obstructive pulmonary disease (36.6%), diabetes (20.7%) and heart failure (16.8%). The strongest pairwise correlation was the combination of heart failure with renal disease (r = 0.20, p < 0.01), and heart failure with diabetes (r = 0.16, p < 0.01). Patients with either one or two or more comorbidities had 40% higher overall mortality risk than those without comorbidities (aHR for comorbidity: 1.4, 95%CI: 1.1–1.7; aHR for multimorbidity: 1.4, 95%CI: 1.1–1.8), when relevant confounding factors were considered. Conclusions The presence of comorbid diseases, rather than the number of comorbidities, was associated with increasing the risk of short-term lung cancer mortality in Spain. Comorbidity was a consistent and independent predictor of mortality among lung cancer patients, six months after diagnosis. The most common comorbid conditions were age-, obesity- and tobacco-related diseases. Our findings highlight the need to develop targeted preventive interventions and more personalised clinical guidelines to address the needs of lung cancer patients with one or more comorbidities in Spain.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…About 90 percent of lung carcinoma identified are large cells, and also linked with elevated rates of development and necrosis and low protection relative to other carcinomas in early stages. Most natural derived anti-cancer medicines are studied and eventually submitted to human trials by cells (including different carcinoma cell lines) and laboratory animals [5]. The amount of recently found chemical products has rising rapidly in current years 5].…”

Section: Original Research Articlementioning

confidence: 99%

“…For the substances in toxicity range, there were about 180,000 [6]. Moreover, the reactions are classified in quantitative terms as 196,000 pharmacologically agile substances [5]. Medicinal plants from certain biologically active substances are often referred to as effective inducers for lung cancer cell apoptosis.…”

Section: Original Research Articlementioning

confidence: 99%

Anti-Cancer Cyclodextrin Nanocapsules Based Formulation Development for Lung Chemotherapy

Pankaj

2021

JPRI

View full text Add to dashboard Cite

Lung carcinoma is one of the highly malignant carcinoma. Oncologists also face a difficulty in handling lung carcinoma. A novel therapeutically strategy in patients with pulmonary cancer may be the immediate injection of chemical-therapeutic agents within lungs. Many drugs are available for in market for treatment of lung cancer but face difficulty due to poor solubility. The paper discusses about development of cyclodextrin modified cationic polymer complex i.e. polyethylene glycol (PEG), wherein the complex is used for providing drug delivery of poorly soluble drugs, more specifically ellipcitine. The complex was made by coating PEG over cyclodextrin nanocapsules wherein the core of the capsule is filled with PEG-7 Glyceryl Cocoate oil for enhancing the delivery of the anti-cancer agent. The complex was then evaluated under characterization studies which includes particle size analysis, zeta potential, morphological analysis, cytotoxicity analysis and anti-cancer effect of the complex. It was found that the complex was more potent in delivering the drug within cancerous cells and was potent to treat lung carcinoma.

show abstract

Lung cancer

Cited by 2 publications

References 3 publications

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study

Anti-Cancer Cyclodextrin Nanocapsules Based Formulation Development for Lung Chemotherapy

Contact Info

Product

Resources

About